德国生物技术 Tubulis 完成 1.28 亿欧元 B2 轮融资，用于临床评估、技术开发和美国扩张。 German biotech Tubulis completes €128M Series B2 financing for clinical evaluation, tech development, and US expansion.

德国生物技术公司 Tubulis 完成 1.28 亿欧元（1.4 亿美元）B2 轮融资，由 EQT Life Sciences 和 Nextech Invest 共同领投。 German biotech company Tubulis completes €128M ($140M) Series B2 financing, co-led by EQT Life Sciences and Nextech Invest. 资金将支持领先 ADC TUB-030、TUB-040 的临床评估、技术开发和美国市场扩张。 Funds will support clinical evaluation of lead ADCs TUB-030, TUB-040, tech development, and US market expansion. Tubulis 为实体瘤靶向打造独特匹配的 ADC，并计划于 2024 年在美国设立子公司并进行 1/2a 期试验。 Tubulis creates uniquely matched ADCs for solid tumor targeting, with plans for a US subsidiary and Phase 1/2a trial in 2024.